| Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner T Liu, V Lam, E Thieme, D Sun, X Wang, F Xu, L Wang, OV Danilova, ... Clinical Cancer Research 27 (17), 4910-4922, 2021 | 27 | 2021 |
| Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma E Thieme, T Liu, N Bruss, C Roleder, V Lam, X Wang, T Nechiporuk, ... Cell death & disease 13 (3), 246, 2022 | 16 | 2022 |
| CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma E Thieme, N Bruss, D Sun, EC Dominguez, D Coleman, T Liu, C Roleder, ... Molecular Cancer 22 (1), 64, 2023 | 8 | 2023 |
| Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies Z Dong, JY Song, E Thieme, A Anderson, E Oh, WA Cheng, BZ Kuang, ... Blood Advances 7 (6), 918-932, 2023 | 4 | 2023 |
| Pharmacologic targeting MCL1 with AZD5991 induces apoptosis and mitochondrial dysfunction in non-Hodgkin lymphoma (NHL) cells T Liu, F Xu, E Thieme, V Lam, G Fan, L Nikolaenko, SE Kurtz, JW Tyner, ... Blood 136, 33, 2020 | 4 | 2020 |
| Transcriptional reprogramming of super-enhancer associated oncogenes following inhibition of cyclin-dependent kinase-9 (CDK9) in aggressive non-Hodgkin lymphoma (NHL) E Thieme, D Sun, GG Sharma, N Bruss, T Liu, DJ Coleman, Z Xia, ... Blood 138, 3493, 2021 | 2 | 2021 |
| Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models E Thieme, V Lam, N Bruss, F Xu, SE Kurtz, JW Tyner, A Danilov, T Liu Blood 136, 29, 2020 | 2 | 2020 |
| Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin … T Liu, V Lam, E Thieme, O Danilova, N Bruss, L Alinari, JW Tyner, ... Blood 140 (Supplement 1), 6016-6017, 2022 | | 2022 |
| Abstract A02: Probing the roles of SUMOylation in B-cell lymphoma cells by using a selective SUMO inhibitor subasumstat (TAK-981) T Liu, V Lam, D Sun, E Thieme, T Nechiporuk, D Bottomly, OV Danilova, ... Blood Cancer Discovery 3 (5_Supplement), A02-A02, 2022 | | 2022 |
| Abstract A06: Strategies to circumvent resistance to cyclin-dependent kinase-9 inhibition (CDK9i) in non-Hodgkin lymphoma (NHL) E Thieme, D Sun, N Bruss, G Sharma, T Liu, D Coleman, T Nechiporuk, ... Blood Cancer Discovery 3 (5_Supplement), A06-A06, 2022 | | 2022 |
| Pharmacologic targeting Mcl-1 with AZD5991 induces apoptosis, suppresses mitochondrial respiration and overcomes ibrutinib resistance in non-Hodgkin lymphoma cells T Liu, V Lam, E Thieme, X Wang, F Xu, S Kurtz, J Tyner, OV Danilova, ... Cancer Research 81 (13_Supplement), 938-938, 2021 | | 2021 |
